Why the Neutral Stance?
Hancock�� focus on its organic growth strategy as well as expansion through acquisitions prompted us to initiate with this stance. Further, the company continues to build capital, resulting in a better financial position that will help in fulfilling the stringent capital requirements. Moreover, with a strong liquidity position and meaningful capital deployment, Hancock remains an asset for yield-seeking investors.
Nevertheless, due to the low interest rate environment, Hancock is expected to continue experiencing pressure on its net interest margin. Moreover, increased non-interest expenses and significant exposure to real estate markets remain major causes of concern for the company. In addition, Hancock�� profitability remains subject to the stringent regulatory landscape.
Hot Regional Bank Stocks To Own Right Now: Powershares Dynamic Large Cap Value Portfolio (PWV)
The PowerShares Dynamic Large Cap Value Portfolio is based on the Dynamic Large Cap Value Intellidex Index. The Fund focuses on providing capital appreciation while maintaining consistent and stylistically accurate exposure.
The Style Intellidexes apply a rigorous ten factor style isolation process to objectively segregate companies into their appropriate investment style and size universe. PowerShares Capital Management LLC is the investment advisor to the Fund.
Advisors' Opinion:- [By Jim Lowell]
PowerShares Dynamic Large Cap Value (PWV) seeks investment results that correspond to the price and yield performance of the Dynamic Large Cap Value Intellidex Index, which seeks to provide capital appreciation while maintaining large cap value exposure.
Hot Regional Bank Stocks To Own Right Now: Furiex Pharmaceuticals Inc (FURX)
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�� product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.
Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). Alogliptin is a DPP-4 inhibitor that slows the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Fluoroquinolone drug candidate is a Phase II-ready novel fluoroquinolone antibiotic that is being developed by the Company for the treatment of complicated skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections. This antibiotic has a spectrum of activity and is able to treat methicillin-resistant staphylococcus aureus (MRSA) infections. The Company is developing both oral and intravenous (IV) formulations. The Company is developing Mu Delta for treatment of diarrheal predominant irritable bowel syndrome (d-IBS). The Company is conducting a Phase II study on an oral formulation of Mu Delta.
The Company is developing PPD 10558 for the treatment of dyslipidemia. PPD 10558 has shown muscle safety in preclinical studies by minimizing the delivery of the drug to the muscle. The Company has filed an inve! stigational new drug (IND) application with the United States Food and Drug Association and completed five clinical studies.
Advisors' Opinion:- [By Jake L'Ecuyer]
Top Headline
Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014. - [By Michael Calia]
Furiex Pharmaceuticals Inc.(FURX) said its treatment for diarrhea-predominant irritable bowel syndrome showed simultaneous improvements in stool consistency and abdominal pain in two Phase III studies. The drug developer’s shares surged 78% to $82 in recent premarket trading.
Top 5 Heal Care Stocks To Own Right Now: MGIC Investment Corp (MTG)
MGIC Investment Corporation (MGIC), incorporated June 21, 1984, is a holding company and through wholly owned subsidiaries is a private mortgage insurer in the United States. As of December 31, 2012, its principal mortgage insurance subsidiaries, Mortgage Guaranty Insurance Corporation (MGIC) and MGIC Indemnity Corporation (MIC), were each licensed in all 50 states of the United States, the District of Columbia and Puerto Rico. During the year ending December 31, 2012, the Company wrote new insurance in each of those jurisdictions in MGIC and/or MIC. The Company capitalized MIC to write new insurance in certain jurisdictions where MGIC no longer meets, and is unable to obtain a waiver of, those jurisdictions��minimum capital requirements. Private mortgage insurance covers losses from homeowner defaults on residential mortgage loans, reducing and, in some instances, eliminating the loss to the insured institution if the homeowner defaults.
Mortgage Insurance
Primary insurance provides mortgage default protection on individual loans and covers unpaid loan principal, delinquent interest and certain expenses associated with the default and subsequent foreclosure. Primary insurance is written on first mortgage loans secured by owner occupied single-family homes, which are one-to-four family homes and condominiums. Primary insurance is also written on first liens secured by non-owner occupied single-family homes, which are referred to in the home mortgage lending industry as investor loans, and on vacation or second homes. Primary coverage can be used on any type of residential mortgage loan instrument approved by the mortgage insurer.
When a borrower refinances a mortgage loan insured by the Company by paying it off in full with the proceeds of a new mortgage that is also insured by it, the insurance on that existing mortgage is cancelled, and insurance on the new mortgage is considered to be new primary insurance written. Therefore, continuation of its coverage fr! om a refinanced loan to a new loan results in both a cancellation of insurance and new insurance written. When a lender and borrower modify a loan rather than replace it with a new one, or enter into a new loan pursuant to a loan modification program, its insurance continues without being cancelled assuming that the Company consent to the modification or new loan.
The borrower�� mortgage loan instrument requires the borrower to pay the mortgage insurance premium. There are several payment plans available to the borrower, or lender, as the case may be. Under the monthly premium plan, the borrower or lender pays it a monthly premium payment to provide only one month of coverage. Under the annual premium plan, an annual premium is paid to it in advance, and it earns and recognizes the premium over the next 12 months of coverage, with annual renewal premiums paid in advance thereafter and earned over the subsequent 12 months of coverage. Under the single premium plan, the borrower or lender pays it a single payment covering a specified term exceeding twelve months.
Pool insurance is used as an additional credit enhancement for certain secondary market mortgage transactions. Pool insurance covers the excess of the loss on a defaulted mortgage loan which exceeds the claim payment under the primary coverage, if primary insurance is required on that mortgage loan, as well as the total loss on a defaulted mortgage loan which did not require primary insurance. Pool insurance is used as an additional credit enhancement for certain secondary market mortgage transactions. Pool insurance covers the excess of the loss on a defaulted mortgage loan, which exceeds the claim payment under the primary coverage, if primary insurance is required on that mortgage loan, as well as the total loss on a defaulted mortgage loan which did not require primary insurance. In general, the loans insured by it in Wall Street bulk transactions consisted of loans with reduced underwriting documentation; cash out! refinanc! es, which exceed the standard underwriting requirements of the Federal National Mortgage Association (Fannie Mae) and Federal Home Loan Mortgage Corporation (Freddie Mac) (collectively GSEs); A- loans; subprime loans, and jumbo loans.
Other Products and Services
The Company has participated in risk sharing arrangements with the GSEs and captive mortgage reinsurance arrangements with subsidiaries of certain mortgage lenders, which reinsure a portion of the risk on loans originated or serviced by the lenders, which have MGIC primary insurance. It provides information regarding captive mortgage reinsurance arrangements to the New York Department of Insurance (known as the New York Department of Financial Services), the Minnesota Department of Commerce and the Department of Housing and Urban Development, (HUD). It performs contract underwriting services for lenders, in which it judges whether the data relating to the borrower and the loan contained in the lender�� mortgage loan application file comply with the lender�� loan underwriting guidelines. It also provides an interface to submit data to the automated underwriting systems of the GSEs, which independently judge the data. These services are provided for loans, which require private mortgage insurance, as well as for loans that do not require private mortgage insurance. It provides mortgage services for the mortgage finance industry, such as portfolio retention and secondary marketing of mortgages.
The Company competes with Federal Housing Administration, Veterans Administration, PMI Mortgage Insurance Company, Genworth Mortgage Insurance Corporation, United Guaranty Residential Insurance Company, Radian Guaranty Inc., CMG Mortgage Insurance Company, and Essent Guaranty, Inc.
Advisors' Opinion:- [By Ben Levisohn]
MGIC Investment (MTG) was not to supposed to turn a profit during the quarter. If the analysts were right, the mortgage insurer’s second-quarter profit was supposed to be a blip and MGIC would return to its money-losing ways.
Associated PressThat’s not quite what happened. MGIC reported a profit of 4 cents a share versus forecasts for a loss of 10 cents, according to FactSet and MGIC’s shares popped 14% to $8.29.
Its big day has also boosted other insurers. Radian Group (RDN) has risen 7.2% to $14.39, while Old Republic International (ORI) has advanced 2.1% to $15.24, Genworth Financial (GNW) is up 3.6% at $13.41 and MBIA Inc. (MBI) has jumped 4.3% to $10.76.
Susquehanna’s Jack Micenko credits a better economy with boosting earnings:
The beat was driven by lower loss reserving – $180 mln versus our estimate of $225 and the consensus estimate of $240, as favorable economic trends helped drive their default book claim rate and severity lower…
Micenko expects MGIC’s shares to hit $13, a 57% gain from its current price.
- [By Dan Caplinger]
MGIC Investment (NYSE: MTG ) will release its quarterly report next Tuesday, but investors haven't waited for that report to send the stock to two-year highs. As the housing market has improved, the mortgage-insurance company's prospects have followed suit, but the slow recovery in MGIC earnings are now vulnerable to a potential drop in premium revenue if rising interest rates hurt new mortgage activity.
- [By David Hanson and Matt Koppenheffer]
In this segment of The Motley Fool's everything-financials show,�Where the Money Is, banking analysts Matt Koppenheffer and David Hanson dicuss earnings from MGIC Investment Corp. (NYSE: MTG ) and look ahead to Radian (NYSE: RDN ) 's (NYSE: RDN ) quarterly results.
- [By George Putnam]
George Putnam: Sure. Well, MGIC Investment Corp. (MTG), which insures mortgages—residential mortgages—was really hammered back in 2007, 2008, and it struggled to, sort of, dig out of the hole that it got in from all of the defaults that individual homeowners made on their mortgages.
Hot Regional Bank Stocks To Own Right Now: Strategic Diagnostics Inc.(SDIX)
Strategic Diagnostics Inc., a biotechnology company, develops, commercializes, and markets proprietary products, services, and solutions for the pharmaceutical, biotechnology, diagnostics, food safety, and environmental markets. Its life science portfolio includes products and custom services that supply critical reagents used across the life science research and development markets. These products and services include custom antibodies, in-vitro diagnostic-grade antibodies, proprietary critical reagent products, associated bio-processing services, and custom assay design and development services that are sold to pharmaceutical, biotechnology, and diagnostic companies, as well as to biomedical research centers. The company also provides Kit products, including immunoassays, which represent advanced technology for the detection of food pathogens and soil contaminants. Its detection technologies allow industrial customers to identify the presence of adulterants, such as chem ical toxins, biological pathogens, and other contaminants, which can compromise human or environmental safety, and/or impact efficiencies of production processes. These products are used in various applications, including food and beverage manufacturing, environmental management, and agriculture and agro-science. The company markets and sells its products in the life sciences, and food safety product categories through a direct sales force, Internet, and a network of distributors, as well as through its corporate partners in the United States, Canada, Mexico, Latin America, Europe, and Asia. Strategic Diagnostics Inc. was founded in 1987 and is headquartered in Newark, Delaware.
Advisors' Opinion:- [By CRWE]
SDIX (Nasdaq:SDIX) – a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic, and food safety applications, expects to release its second quarter 2012 results at approximately 4 p.m. ET on Wednesday, August 8, 2012.
Hot Regional Bank Stocks To Own Right Now: Orexigen Therapeutics Inc.(OREX)
Orexigen Therapeutics, Inc., a development stage company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed phase III clinical trials; and Empatic that has completed phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; and naltrexone is a treatment for alcohol and opioid addiction. The company?s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide is for the adjunctive treatment of partial seizures, a form of epilepsy. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave. Orexigen Therapeutics, Inc. was founded in 2002 and is based in La Jolla, California.
Advisors' Opinion:- [By Brian Orelli]
VIVUS' direct competitors in the obesity space both have large partners. Arena Pharmaceuticals (NASDAQ: ARNA ) secured a marketing deal with Eisai to market Belviq, and Orexigen (NASDAQ: OREX ) will have help from Takeda once its obesity drug, Contrave, is approved.
Hot Regional Bank Stocks To Own Right Now: Genuine Parts Company (GPC)
Genuine Parts Company distributes automotive replacement parts, industrial replacement parts, office products, and electrical/electronic materials in the United States, Puerto Rico, Canada, and Mexico. The company operates in four segments: Automotive Parts Group, Industrial Parts Group, Office Products Group, and Electrical/Electronic Materials Group. The Automotive Parts Group segment distributes automotive replacement parts for imported vehicles, trucks, SUVs, buses, motorcycles, recreational vehicles, farm vehicles, small engines, farm equipment, and heavy duty equipment. This segment also distributes accessory items used in the automotive aftermarket, such as repair shops, service stations, fleet operators, automobile and truck dealers, leasing companies, bus and truck lines, mass merchandisers, farms, industrial concerns, and individuals. It owns and operates automotive parts distribution centers and automotive parts stores under the NAPA name. The Industrial Parts G roup segment distributes industrial replacement parts and related supplies, such as bearings, mechanical power transmission, industrial automation, hose, hydraulic and pneumatic components, industrial supplies, and material handling products. This segment serves various industries, including the food, forest products, primary metal, paper, mining, automotive, petrochemical, and pharmaceutical industries. The Office Products Group segment involves in the wholesale distribution of a line of office and other business related products that are used in the daily operation of businesses, schools, offices, and institutions. The Electrical/Electronic Materials Group segment distributes insulating and conductive materials, assembly tools, test equipment, and custom fabricated parts. This segment provides distribution services to original equipment manufacturers, motor repair shops, and assembly markets. The company was founded in 1928 and is headquartered in Atlanta, Georgia.
Advisors' Opinion:- [By Lawrence Meyers]
That’s just one reason DD, with its 2.8% yield, is still one of the best dividend stocks. Plus, the payout has historically been about 50% of free cash flow.
Death-Defying Dividend Stocks: Genuine Parts Co. (GPC)Dividend Yield: 2.53%
- [By Dan Caplinger]
Genuine Parts (NYSE: GPC ) is hardly a household name, but you'll find it among the largest producers of auto parts in the industry, and its NAPA Auto Parts stores are widely known among vehicle owners and mechanics alike. Unlike Ford and GM, you'll also find Genuine Parts on the list of Dividend Aristocrats, where admission is determined by whether a company can manage to boost its dividend payouts to shareholders every single year for at least a quarter century. Only a few dozen stocks make the cut, demonstrating their staying power even through tough times. Let's take a closer look at Genuine Parts to see whether it can use recent success in the auto industry to sustain its long streak of rewarding dividend payouts to investors.
- [By Tabitha Jean Naylor]
But no matter how good the quality is there is always going to be a need for auto parts with any car on a long enough timeline. What sets O'Reilly apart from other big contenders like Napa Auto Parts (NYSE: GPC) or Pep Boys�(NYSE: PBY) is that O'Reilly has a unique model for selling to both traditional customers as well as to professional garages. It is expected the company will see between five and six percent growth over the next five to eight years.
Hot Regional Bank Stocks To Own Right Now: Sucampo Pharmaceuticals Inc (SCMP)
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�� prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�� products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl).
AMITIZA
The Company�� AMITIZA is being marketed in the United States for three gastrointestinal indications under a license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. The three gastrointestinal indications include chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration (FDA), in April 2013. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd. (Abbott), for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. In Switzerland, the Company is marketing AMITIZA.
RESCULA
The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People�� Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP), in patients with open-angle glaucoma or ocular hypertension in the United States. RESCULA may be used as an agent or concomit! antly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.
Advisors' Opinion:- [By James Brumley]
Still, for the nimble who know when to get out, OREX is one of the few cheap stocks worth a closer look.
Sucampo Pharmaceuticals (SCMP)Finally, though the price of $7.60 clearly qualifies it as one pf the cheapest of the cheap stocks out there in the pharmaceutical world, that’s not the reason Sucampo Pharmaceuticals (SCMP) may be worth a look here. It’s the 30% slide we’ve seen SCMP stock suffer since peaking in mid-January. It’s not a pullback that’s bound to go unchallenged by the bulls.
Hot Regional Bank Stocks To Own Right Now: Dorchester Minerals L.P.(DMLP)
Dorchester Minerals, L.P. engages in the acquisition, ownership, and administration of producing and non-producing natural gas and crude oil royalty, net profits, and leasehold interests in the United States. Its net profits interests represent net profits overriding royalty interests in various properties owned by the operating partnership; and royalty properties consist of producing and nonproducing mineral, royalty, overriding royalty, net profits, and leasehold interests located in 574 counties and parishes in 25 states. Dorchester Minerals Management LP serves as the general partner of Dorchester Minerals, L.P. The company was founded in 1982 and is based in Dallas, Texas.
Advisors' Opinion:- [By Robert Rapier]
Q: The writer before you did not like Dorchester. Could you research it and give a recommendation by the next chat?
Dorchester Minerals (Nasdaq: DMLP) is a Texas-based partnership that owns producing and non-producing crude oil and natural gas properties, royalty, overriding royalty, net profits, and leasehold interests. The partnership is primarily a natural gas producer, and the biggest knock against it historically is that it hasn’t done a great job of growing proved reserves:
Dorchester Minerals Reserves History. Source: Dorchester Minerals Investor Presentation
No comments:
Post a Comment